This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
